JW Asset Management Trims Liquidia Stake

JW Asset Management reduced its stake in Liquidia Corporation, a biotech firm specializing in pulmonary hypertension treatments, by selling shares worth $3.1 million. Despite the sale, JW still holds a significant position in Liquidia, which has seen a remarkable 175% increase in share price over the past year. Liquidias flagship product, YUTREPIA, generated $148.3 million in net sales last year, with a strong fourth quarter performance. The company ended the year with $190.7 million in cash and filled over 3,600 prescriptions for more than 2,900 patients. JWs move appears to be a strategic profit-taking, as they remain invested in Liquidias growth potential. Investors should watch Mondays first-quarter earnings for further insights into Liquidias momentum. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7469d639efec55a9